These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33837906)

  • 1. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm.
    Pouladzadeh M; Safdarian M; Eshghi P; Abolghasemi H; Bavani AG; Sheibani B; Moradi Choghakabodi P; Feghhi A; Ghafourian Boroujerdnia M; Forouzan A; Jalali Far MA; Kaydani GA; Rajaei E; Amin M; Torabizadeh M; Yousefi F; Hadaddezfuli R
    Intern Emerg Med; 2021 Nov; 16(8):2181-2191. PubMed ID: 33837906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 convalescent plasma composition and immunological effects in severe patients.
    Acosta-Ampudia Y; Monsalve DM; Rojas M; Rodríguez Y; Gallo JE; Salazar-Uribe JC; Santander MJ; Cala MP; Zapata W; Zapata MI; Manrique R; Pardo-Oviedo JM; Camacho B; Ramírez-Santana C; Anaya JM;
    J Autoimmun; 2021 Mar; 118():102598. PubMed ID: 33524876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of COVID-19, with cytokine storm, treated by consecutive use of therapeutic plasma exchange followed by convalescent plasma transfusion: A case report.
    Ragab D; Salah-Eldin H; Afify M; Soliman W; Badr MH
    J Med Virol; 2021 Apr; 93(4):1854-1856. PubMed ID: 33107628
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of convalescent plasma transfusion for the treatment of severely ill COVID-19 patients in Pakistan.
    Khan TNS; Mukry SN; Masood S; Meraj L; Devrajani BR; Akram J; Fatima N; Maqsood S; Mahesar A; Siddiqui R; Ishaque S; Afzal MB; Mukhtar S; Ahmed S; Naz A; Shamsi TS
    BMC Infect Dis; 2021 Sep; 21(1):1014. PubMed ID: 34579646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
    Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
    Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
    ; Estcourt LJ; Turgeon AF; McQuilten ZK; McVerry BJ; Al-Beidh F; Annane D; Arabi YM; Arnold DM; Beane A; Bégin P; van Bentum-Puijk W; Berry LR; Bhimani Z; Birchall JE; Bonten MJM; Bradbury CA; Brunkhorst FM; Buxton M; Callum JL; Chassé M; Cheng AC; Cove ME; Daly J; Derde L; Detry MA; De Jong M; Evans A; Fergusson DA; Fish M; Fitzgerald M; Foley C; Goossens H; Gordon AC; Gosbell IB; Green C; Haniffa R; Harvala H; Higgins AM; Hills TE; Hoad VC; Horvat C; Huang DT; Hudson CL; Ichihara N; Laing E; Lamikanra AA; Lamontagne F; Lawler PR; Linstrum K; Litton E; Lorenzi E; MacLennan S; Marshall J; McAuley DF; McDyer JF; McGlothlin A; McGuinness S; Miflin G; Montgomery S; Mouncey PR; Murthy S; Nichol A; Parke R; Parker JC; Priddee N; Purcell DFJ; Reyes LF; Richardson P; Robitaille N; Rowan KM; Rynne J; Saito H; Santos M; Saunders CT; Serpa Neto A; Seymour CW; Silversides JA; Tinmouth AA; Triulzi DJ; Turner AM; van de Veerdonk F; Walsh TS; Wood EM; Berry S; Lewis RJ; Menon DK; McArthur C; Zarychanski R; Angus DC; Webb SA; Roberts DJ; Shankar-Hari M
    JAMA; 2021 Nov; 326(17):1690-1702. PubMed ID: 34606578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of the Appropriate Control Group Is Essential in Evaluating the Cytokine Storm in COVID-19.
    Vassiliou AG; Dimopoulou I; Jahaj E; Keskinidou C; Mastora Z; Orfanos SE; Kotanidou A
    In Vivo; 2021; 35(2):1295-1298. PubMed ID: 33622933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering the COVID-19 cytokine storm: Systematic review and meta-analysis.
    Mulchandani R; Lyngdoh T; Kakkar AK
    Eur J Clin Invest; 2021 Jan; 51(1):e13429. PubMed ID: 33058143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease.
    AlQahtani M; Abdulrahman A; Almadani A; Alali SY; Al Zamrooni AM; Hejab AH; Conroy RM; Wasif P; Otoom S; Atkin SL; Abduljalil M
    Sci Rep; 2021 May; 11(1):9927. PubMed ID: 33976287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
    Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
    BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convalescent plasma therapy in patients with severe COVID-19, A single-arm, retrospective study.
    Ghadami L; Hasibi M; Asadollahi-Amin A; Asanjarani B; Farahmand M; Abdollahi H
    Microb Pathog; 2022 Apr; 165():105482. PubMed ID: 35288278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019].
    Chen C; Zhang XR; Ju ZY; He WF
    Zhonghua Shao Shang Za Zhi; 2020 Jun; 36(6):471-475. PubMed ID: 32114747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological and inflammatory profiles during acute and convalescent phases of severe/ critically ill COVID-19 patients.
    Chen Q; Yu B; Yang Y; Huang J; Liang Y; Zhou J; Li L; Peng X; Cheng B; Lin Y
    Int Immunopharmacol; 2021 Aug; 97():107685. PubMed ID: 33951560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Menichetti F; Popoli P; Puopolo M; Spila Alegiani S; Tiseo G; Bartoloni A; De Socio GV; Luchi S; Blanc P; Puoti M; Toschi E; Massari M; Palmisano L; Marano G; Chiamenti M; Martinelli L; Franchi S; Pallotto C; Suardi LR; Luciani Pasqua B; Merli M; Fabiani P; Bertolucci L; Borchi B; Modica S; Moneta S; Marchetti G; d'Arminio Monforte A; Stoppini L; Ferracchiato N; Piconi S; Fabbri C; Beccastrini E; Saccardi R; Giacometti A; Esperti S; Pierotti P; Bernini L; Bianco C; Benedetti S; Lanzi A; Bonfanti P; Massari M; Sani S; Saracino A; Castagna A; Trabace L; Lanza M; Focosi D; Mazzoni A; Pistello M; Falcone M;
    JAMA Netw Open; 2021 Nov; 4(11):e2136246. PubMed ID: 34842924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report.
    Omrani AS; Zaqout A; Baiou A; Daghfal J; Elkum N; Alattar RA; Bakdach D; Abusriwil H; Mostafa AM; Alhariri B; Ambra N; Khatib M; Eldeeb AM; Merenkov Z; Fawzi Z; Hmissi SM; Hssain AA; Coyle PV; Alsoub H; Almaslamani MA; Alkhal A
    J Med Virol; 2021 Mar; 93(3):1678-1686. PubMed ID: 32965715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19.
    Raadsen MP; Gharbharan A; Jordans CCE; Mykytyn AZ; Lamers MM; van den Doel PB; Endeman H; van den Akker JPC; GeurtsvanKessel CH; Koopmans MPG; Rokx C; Goeijenbier M; van Gorp ECM; Rijnders BJA; Haagmans BL
    J Clin Immunol; 2022 Feb; 42(2):232-239. PubMed ID: 34767118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.